強気
$4.04
シナリオ価格
$22.490
-0.252 (-1.12%)終値時点
Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
Fortrea Holdings Inc is a good buy right now due to its current price of $20.84, which is below the analyst price target of $23 from Barclays, indicating potential upside. Additionally, the stock has shown a strong 1-year change of +112.22%, reflecting significant growth over the past year. The main risk is the high insider selling activity, which has increased by 267.54% over the last month, indicating potential concerns from insiders about the company's future performance.
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

Latest Wall Street Rating Updates

Latest Wall Street Ratings and Price Target Adjustments

Fortrea Grants Stock Awards to New Employees

Fortrea Acquires Early Phase Services Division, Stock Rises

Fortrea Acquires Worldwide's Early Phase Services for $45 Million
Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).
Fortrea Holdings Inc is a good buy right now due to its current price of $20.84, which is below the analyst price target of $23 from Barclays, indicating potential upside. Additionally, the stock has shown a strong 1-year change of +112.22%, reflecting significant growth over the past year. The main risk is the high insider selling activity, which has increased by 267.54% over the last month, indicating potential concerns from insiders about the company's future performance.
投稿はまだありません
登録またはログインして議論に参加本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。